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Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene
expression and protein production lead to high IGFBP-2 content in
malignant ovarian cyst fluid
H Kanety', M Kattan2, I Goldberg3, J Kopolovic3, J Ravia2, J Menczer4 and A Karasik'
Institutes of'Endocrinology, 2Human Genetics andDepartments of3Pathology and4Gynecology, Chaim Sheba Medical Center, and
Tel-Aviv University Sackler School ofMedicine, Tel-Hashomer, Israel 52621.
Summary Expression of insulin-like growth factor-I (IGF-I), its receptor and IGF-binding proteins (IGFBPs)
by ovarian cancer cells and its mitogenic effect on these cells in vitro, suggest that IGF-I may have a role in
regulation of human ovarian cancer. We have recently shown IGFBP-2 to be markedly elevated in malignant
ovarian cyst fluid in vivo. To identify the origin of increased IGFBP-2 in these cyst fluids, the gene expression
and protein content of IGFBP-2 were investigated in 14 malignant and four benign epithelial ovarian
neoplasms. IGFBP-2 mRNA was detected in all ovarian specimens and was 2- to 30-fold higher in malignant
than in benign neoplasms. Within the malignant tissues IGFBP-2 mRNA levels correlated with the
aggressiveness of the tumour and were higher in invasive tumours than in those with borderline pathology.
Southern blot analysis revealed no amplification of IGFBP-2 gene in the DNA samples from ovarian tumours
regardless of their nature. IGFBP-2 was the major binding protein in tissue extracts, as measured by both
Western ligand blotting and immunoblotting, and was significantly higher in malignant than in benign
neoplasms. These findings were further supported by immunohistochemical detection of IGFBP-2 in tumour
sections. Our data suggest that increased local production by the tumour in vivo is responsible for the increased
IGFBP-2 levels in the cyst fluid bathing the ovarian malignancy. This may represent an autocrine regulatory
mechanism for IGF-I proliferative effect of ovarian cancer.
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Insulin-like growth factors' (IGFs) effects on cell proliferation
are determined by an interplay between the ligands, their
receptors as well as multiple IGF-binding proteins (Jones and
Clemmons, 1995; LeRoith et al., 1995). To date, six IGFBPs
have been cloned from human tissues designated IGFBP-1 to
IGFBP-6 (Shimasaki and Ling, 1991). All IGFBPs are
proteins of 200-300 amino acids with a molecular weight
of 24-43 kDa and are synthesised ubiquitously. Beyond their
capacity as carriers, IGFBPs regulate IGF impact on cell
proliferation by modulating its access to the IGF receptors
(Jones and Clemmons, 1995). Therefore, increased IGF
action in aberrant growth can occur secondary to alterations
in IGFBP levels or function induced by the target cell. For
example, proteolysis of IGFBP-3 by prostate-specific antigen
(PSA) is suggested to increase availability of IGF-I to
prostate tumour cells, which produce PSA (Cohen et al.,
1992; Kanety et al., 1993). Alternatively, increased presence
of IGFBP-3 in colon cancer cell culture has been shown to
promote IGF-I effect through anchoring of IGFBP-3 on the
cell membrane, which facilitates IGF-I access to its receptor
(Singh et al., 1994).
We have recently reported IGFBP-2 to be significantly
higher in cyst fluid from invasive malignant than from benign
epithelial ovarian neoplasms (Karasik et al., 1994). Serum
IGFBP-2 levels were also higher in women with invasive
malignancy than in women with benign neoplasms. More-
over, IGFBP-2 was higher in cyst fluids than in the
corresponding sera, implying local production of this
protein. The current work was aimed at better understanding
the origin and role of IGFBP-2 in ovarian cancer.
Materials and methods
Tissue samples
Upon removal, tumours were dissected, frozen immediately
in liquid nitrogen and kept at -80°C until analysed. Parallel
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histopathological examination revealed 14 malignant epithe-
lial ovarian tumours (three serous borderline, five serous
invasive, six metastasis from serous invasive) and four benign
ovarian neoplasms (two adenofibromas, mucinous endome-
trioid, serous cyst). Borderline cases were included in the
malignant group although they are not invasive; wherever
possible their results are displayed separately.
RNA, protein and DNA extraction
Frozen tissues were homogenised in TRI reagent (Molecular
Research Center, Cincinnati, OH, USA) and extracted with
chloroform. Total RNA was isolated from the aqueous
phase, and proteins were precipitated from the organic phase
with isopropanol, according to the manufacturer's directions.
Proteins were dissolved in 1% sodium dodecyl sulphate
(SDS) and further analysed by Western ligand blotting or
immunoblotting. For extraction of DNA, tissues were ground
in liquid nitrogen into fine powder and incubated for 2 h at
55°C in a 10 mM Tris buffer, pH 7.5, containing 50 mM
EDTA, 100 mM sodium chloride, 0.5% sarcosyl and
200 ig ml-' proteinase K. After overnight incubation at
37°C with proteinase K the samples were extracted twice with
phenol and once with phenol/chloroform, chloroform, and
DNA was precipitated with ethanol.
Western ligand blotting and immunoblotting
Samples were analysed by electrophoresis on 12% SDS-
polyacrylamide gels under non-reducing conditions and
transferred to nitrocellulose paper. All IGFBPs were
detected by incubating the membrane with ['25I]IGF-I as
previously described (Karasik et al., 1994). To detect IGFBP-
2 specifically, blots were incubated with rabbit antiserum
against bovine IGFBP-2 (Upstate Biotechnology, Lake
Placid, NY, USA), followed by incubation with anti-rabbit
immunoglobulin G (IgG) peroxidase linked and a chemilu-
minescent peroxidase substrate (Amersham, Aylesbury, UK),
and the membrane was exposed briefly to autoradiographic
film (Karasik et al., 1994). The IGFBP-2 antibody identifies
human IGFBP-2 and has cross-reactivities of <0.5%,I IGFBPs in ovarian cancer
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<0.2%, <0.1% and <0.1% with IGFBP-1, IGFBP-3,
IGFBP-4 and IGFBP-5 respectively (manufacturer's data).
Northern blot analysis
A sample of 30 jug of total RNA was size-fractionated on
1.2% agarose gel containing 2.2 M formaldehyde and
transferred to Nytran membranes (Schleicher & Schuell).
An RNA ladder (BRL, Gaithersburg, MD, USA) was run
in parallel with the samples to allow sizing of the mRNA.
The cDNA probes for hIGFBP-2 and -3 were a kind gift
from N Ling and S Shimasaki (Whittier Institute, La Jolla,
CA, USA). IGFBP-2 (446 bp EcoRI-HindIII fragment) and
IGFBP-3 (475 bp HindIII-EcoRI fragment) human cDNA
probes were radiolabelled using the multiprime labelling kit
(Amersham) with [a-32P]dCTP. Hybridisation was performed
in 0.5 M phosphate buffer, 1% bovine serum albumin and
7% SDS for 16 h at 65°C. Membranes were washed in
0.1% SDS, 0.1 x SSC at 65°C and exposed to autoradio-
graphy. After autoradiography, the IGFBP probe was
stripped and the filters were rehybridised with 32P-labelled
antisense 18S rRNA probe, a kind gift from S Ferber
(Sheba Medical Center, Israel). The intensities of the
autoradiographic signals were quantified by computing
laser densitometry (Densitometer 300A, Molecular Dy-
namics, CA, USA). IGFBP-2 densitometric values were
corrected with corresponding 18S values to eliminate
variations in RNA loading.
Southern blot analysis
Genomic DNA (5 Mg) was digested with either EcoRI or
HindIII and fractionated on 0.7% agarose gel. DNA was
transferred onto Nytran membranes and hybridisation was
performed as described for Northern blots.
Tissue localisation ofIGFBP-2 by immunohistochemistry
Paraffin-embedded tissue sections (4 Mrm-thick) were depar-
affinised, hydrated through xylene-graded alcohol series,
treated with 3% hydrogen peroxide (H202) to neutralise
endogenous peroxidase, washed in Tris buffer (pH 7.6) and
incubated with rabbit antiserum against bovine IGFBP-2
(1:200) or rabbit antiserum against human IGFBP-3 (1:200)
for 30 min at room temperature. Sections were washed
extensively and then incubated with biotinylated anti-rabbit
IgG for 30 min, followed by incubation for an additional
30 min with streptavidin-conjugated horseradish peroxidase
using a commercial kit (Dako, Cappinteria, CA, USA)
according to the manufacturer's directions. The antibody-
bound peroxidase was visualised with 3'aminoethylcarbazole
(AEC). Slides were counterstained in Mayer's haematoxylin
before microscopic examination. Control sections were
stained in parallel with normal rabbit IgG or with buffer
alone. Neither control exhibited detectable staining.
Statistical analysis
Comparison of IGFPB-2 mRNA levels between groups was
calculated using the two-tailed Wilcoxon rank sum test.
Results
IGFBPs in primary ovarian neoplasms
IGFBPs in protein extracts prepared from primary benign
and malignant epithelial ovarian neoplasms were evaluated
by Western ligand blotting and immunoblotting. As depicted
in Figure 1, the 32 kDa IGFBP-2 was the major IGFBP in
tissue extracts of all ovarian neoplasms. It was significantly
higher in malignant (Figure 1, five right lanes) than in benign
neoplasms (Figure 1, two left lanes). Low levels of 24, 29, 40
and 43 kDa IGFBPs were also observed in some of the
extracts obtained from malignant neoplasms (Figure 1).
Immunohistochemical localisation of IGFBP-2
To ascertain that IGFBP-2 is localised in epithelial neoplastic
ovarian tissues, specimens were evaluated by immunohisto-
chemical staining with IGFBP-2-specific antibody (Figure 2).
The sections in Figure 2 were taken from a benign serous
papillary cystadenoma (Figure 2a) and a poorly differentiated
serous cystadenocarcinoma (Figure 2b). The cytoplasm of
both the benign and malignant epithelium stained positive for
IGFBP-2. Neither sample stained positive with an IGFBP-3
antibody (not shown). The stroma surrounding these
structures did not stain positive for either IGFBP-2 (Figure
2) or IGFBP-3 (not shown).
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Figure 1 Autoradiographs of Western ligand blots and
immunoblots of IGFBPs in primary ovarian neoplasms. Equal
amounts (80,Mg) of tissue extracts from benign, borderline and
malignant ovarian neoplasms were analysed in each lane. The blot
in the upper panel was probed with labelled IGF-I, whereas in the
lower panel detection of IGFBP-2 was carried out with a specific
antibody. Numbers on the left axis represent molecular weight
(Mr) standards. The identities of individual IGFBPs are listed on
the right.
:@bK~ i ,
... _ *77.
.: :%.4- _. *..... S. l i,:...:
E ..r . 4* , awS.
Figure 2 Localisation of IGFBP-2 in ovarian neoplasms by
immunohistochemistry. Sections of benign serous papillary
cystadenoma (a) and malignant poorly differentiated serous
cystadenocarcinoma (b) neoplasms were analysed with IGFBP-2
antibody (magnification x 110).
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To evaluate further the origin of the high IGFBP-2 levels
observed in ovarian malignant neoplasms, RNA isolated from
benign (Ben, n=4), borderline malignant (B, n= 3), invasive
primary (I, n = 5) and metastatic (M, n=6) ovarian neoplasms
was assayed for IGFBP-2 gene expression. The 1.4 kb IGFBP-
2 transcript was detected in all ovarian specimens and was
significantly higher (2- to 30-fold) in invasive malignant
compared with benign neoplasms (Figure 3). Within the
malignant tissues, mean IGFBP-2 mRNA levels correlated
with the aggressiveness of the tumour and were higher
(P=0.01) in invasive tumours than in all others (Figure 4).
Interestingly, IGFBP-2 mRNA was more abundant in primary
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invasive tumours than in their metastases. IGFBP-2 gene
expression in primary tumours was also compared with that of
IGFBP-3 in the same Northern blots (Figure 5). The 2.5 kb
IGFBP-3 transcript in RNA from malignant tissues was much
less abundant than IGFBP-2 as evidenced by the longer
exposure times required for their detection by autoradiogra-
phy. Moreover, unlike IGFBP-2, IGFBP-3 mRNA levels did
not correlate with the tumour histological nature.
Southern blot analysis
To evaluate whether the overexpression of IGFBP-2 results
from gene amplification, genomic DNA prepared from
malignant ovarian neoplasms was digested with EcoRI or
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Figure 3 IGFBP-2 gene expression in ovarian epithelial tumours. Autoradiographs of Northern blots sequentially probed with an
IGFBP-2 cDNA (top) and with a 18S rRNA antisense oligonucleotide probe (bottom). Ben, benign ovarian neoplasm; B, borderline
ovarian neoplasm; I, invasive ovarian tumours; M, metastatic ovarian tumour.
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Figure 4 Relative IGFBP-2 expression in primary and metastatic
ovarian tumours. Autoradiographs of Northern blots analysing
IGFBP-2 and 18S from ovarian tumours were scanned and
density in the IGFBP-2 signals was normalised to the
corresponding density of the 18S band. Normalised densitometry
results (means) are expressed relative to that of benign ovarian
tumours which were assigned the value of 1.
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Figure 5 IGFBP-2 and IGFBP-3 gene expression in primary
ovarian tumours. Autoradiographs of Northern blots sequentially
probed with IGFBP-2 cDNA (top) and IGFBP-3 cDNA
(bottom). Abbreviation as in Figure 3. A 24h exposure is shown
for the upper panel and a 96h exposure for the lower panel.
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Figwe 6 Southern blot analysis ofIGFBP-2 m ovarian tumours.
Genomic DNA was digested with EcoRI (left panel) or Hmdlll
(right panel) and analysed by Southern blotting with IGFBP-2
cDNA. DNA extracted from leucocytes of healthy individuals
was used as control.
HindIII and analysed by Southern blotting with IGFBP-2
cDNA (Figure 6). DNA extracted from leucocytes of healthy
individuals was used as control. Southern blot analysis
revealed no amplification of IGFBP-2 gene in the DNA
samples from ovarian tumours.
Eiscsioe
IGFBP-2 was found to be consistently elevated in serum and
extracellular fluids surrounding tumours in patients with
malignancy of different origin, such as Wilm's tumour
(Zumkeller et al., 1993), prostate cancer (Kanety et al.,
1993), lung cancer (Reeve et al, 1990) and others. Our
previous finding of high levels of IGFBP-2 in cyst fluid and
serum from patients with ovarian malignant neoplasms
(Karasik et al., 1994) is in line with these reports. Tumour-
derived cell lines including cells from ovarian origin express
and produce IGFBP-2 (Yee et al., 1991; Reeve et al., 1992;
Hofmann et al., 1994). Ovarian cancer tissues were also
shown to express preferentially IGFBP-2 (Krywicki et al.,
1993). In the current study we have supplied evidence that the
source of the increase in IGFBP-2 levels in body fluids of
patients with ovarian malignancy is overproduction of
IGFBP-2 by the tumour itself. Moreover, in the more
invasive tumours IGFBP-2 mRNA was more abundant.
The biological significance of these findings is less obvious.
IGFBPs have three major functions that are essential in
regulating the biological effects of IGFs (Jones and
Clemmons, 1995): they serve as a storage pool and
determine the metabolic fate of IGFs; they may inhibit
IGFs' effect by competing with the IGF receptors; and they
may potentiate IGFs' effect by targeting them to specific cells
and tissues. Addition of the various IGFBPs in vitro to
different transformed cells resulted in both suppressive or
facilitatory effects on IGF actions. Transfection experiments
aimed at constitutively increasing the production of IGFBPs
also resulted in conflicting effects. In BALB/c3T3 cells
expression of recombinant IGFBP-3 resulted in growth
inhibition of these cells (Cohen et al., 1993), whereas in
MCF-7 breast carcinoma cells IGFBP-3 overexpression
increased cell proliferation upon IGF-I treatment (Chen et
al., 1994). IGFBP-2 has been shown to inhibit IGF-
stimulated DNA synthesis and mitogenesis in fibroblasts
(Schwander et al., 1989) and human lung carcinoma cell lines
in culture (Reeve et al., 1993). In contrast, IGF-I effects were
increased by addition of purified IGFBP-2 to microvascular
endothelial cells (Bar et al., 1989), aortic smooth muscle cells
(Bourner et al., 1992) and breast carcinoma cells (Chen et al.,
1994). These contradictory results may be explained by
multiple factors that are present or absent in the specific
experimental system. Proteases which proteolyse IGFBPs and
reduce their affinity to IGFs (Conover et al., 1993) as well as
other modifications (phosphorylation) (Jones et al., 1991)
may be responsible for the observed differences. These points
underline the caution that should be exercised in interpreting
the biological role of increased IGFBP-2 production by the
ovarian neoplasms. Nevertheless, this demonstration of
increased IGFBP-2 production in situ and especially the
correlation between the mRNA overexpression and the
invasiveness of the tumour suggest that IGFBP-2 may
stimulate cell growth or invasiveness. Under this specula-
tion, increased production of IGFBP-2 may represent an
autocrine mechanism by which the invasive tumour perpe-
tuates and augments its own growth and development. Of
interest is the observation that metastases contain low
IGFBP-2 mRNA in comparison with the ovarian tumour
source. This may result potentially from a paracrine effect of
ovarian tissue that may induce IGFBP-2 expression.
Oestrogens may be a potential mediator of such an effect,
as oestradiol has been shown to induce IGFBP-2 expression
in breast cancer cells in correlation with positive oestrogen
receptor content (Yee et al., 1991). Moreover, we have
described a correlation between the E2 and IGFBP-2 content
in cyst fluids from ovarian tumours (Karasik et al., 1994).
Gene amplification is one of the mechanisms leading to
overexpression of proteins in malignancy. We have excluded
IGFBP-2 gene amplification as the mechanism for the
increased expression but did not pursue other possibilities.
One clue for an investigative direction comes from a recent
study (Kutoh et al., 1993) which identified a silencer domain
of the rat IGFBP-2 gene. This domain contains target
sequences termed RCE, for retinoblastoma gene product, a
well-characterised tumour-suppressor gene. This finding
suggests a possible interplay between tumour-suppressor
genes altered in malignancy which may lead to increased
IGFBP-2 expression and, in turn, may increase tumour
invasiveness through augmenting IGF mitogenic action.
The consistent correlation between tumour invasiveness
and IGFBP-2 mRNA overexpression in ovarian neoplasms
calls for a verification and follow-up in a larger sample of
patients, as it can be a potential prognostic factor used to
predict tumour aggressiveness.
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